Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Packerfan666on Dec 25, 2018 6:55pm

103 Views

Post# 29156822

RE:RE:RE:RE:RE:The January Effect

Actually Kaly usually performs strong January -April and then May - November goes on a downward slide. 2 more News releases coming. Let’s see if they are worth anything to bring stock price up from these insane lows. I am just shocked with these kind of results on low dose how can people not be more excited . These results were on low dose. Wasn’t even supposed to be particularly effective. Oh well. What can we do

Bullboard Posts

Visionstate set to leverage success in the U.S. market